Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysisResearch in context
Summary: Background: Most cancer drugs enter the US market first. US Food and Drug Administration (FDA) approvals of new cancer drugs may influence regulatory decisions in other settings. The study examined whether characteristics of available evidence at FDA approval influenced time-to-marketing au...
Saved in:
Main Authors: | Adriana M. Ivama-Brummell (Author), Fernanda L. Marciniuk (Author), Anita K. Wagner (Author), Claudia G.S. Osorio- (Author), Sabine Vogler (Author), Elias Mossialos (Author), Carla L. Tavares- (Author), Huseyin Naci (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmaceutical Pricing and Reimbursement Policies: lessons learnt and perspectives for Brazil
by: Adriana M. IVAMA-BRUMMELL, et al.
Published: (2022) -
Medicines regulation, pricing and reimbursement in Brazil
by: Adriana M. IVAMA-BRUMMELL, et al.
Published: (2022) -
The regulatory, evaluation, pricing and reimbursement pathway for medicines in the UK: combining innovation and access
by: Adriana M. IVAMA-BRUMMELL, et al.
Published: (2022) -
Overview of drugs approved by the FDA in 2022
by: D. V. Kurkin, et al.
Published: (2023) -
FDA approved ready to use phenylephrine
by: Pradeep Kumar Bhatia, et al.
Published: (2021)